Article

Gold Micro-Shunt offers good IOP reduction without bleb

The SOLX Gold Micro-Shunt (GMS, OccuLogix) is a novel approach to treating increased IOP in patients with open-angle glaucoma that does not respond to other therapies and is a good alternative to trabeculectomy, according to Shlomo Melamed, MD, an investigator based in Tel Aviv, Israel.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Related Content
(Image credit: AdobeStock/©rh2010)
April 10th 2025

Presbyopia treatment success begins with patient-centered care

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
March 20th 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension
March 13th 2025

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension

Optimization of IOL selection and techniques enhances cataract surgery outcomes
February 26th 2025

Optimization of IOL selection and techniques enhances cataract surgery outcomes

© 2025 MJH Life Sciences

All rights reserved.